

TABLE 2 Risk factors of toxicity and methotrexate clearance delay at 44h.

Characteristics	Toxicity			Methotrexate clearance delay at 44h		
	Grade0/1/2=0, Grade3/4=1			No($\leq 1\mu\text{mol/L}$)=0, Yes($> 1\mu\text{mol/L}$)=1		
	P value	OR	95% CI	P value	OR	95% CI
Age ($\leq 6^*$ vs > 6 years)	0.131	1.491	0.887-2.506	0.002	1.583	1.186-2.112
Sex (female* vs male)	0.026	0.704	0.517-0.960	0.003	1.545	1.162-2.055
Immunophenotype (B-ALL* vs T-ALL)	0.603	1.153	0.675-1.970	0.867	1.040	0.655-1.652
Risk group (LR* vs IR/HR)	0.016	1.491	1.078-2.060	<0.001	1.950	1.452-2.617
Cycle n						
C1*	0.026			<0.001		
C2	0.502	0.872	0.585-1.3	0.150	0.771	0.541-1.099
C3	0.121	0.718	0.473-1.091	<0.001	0.498	0.343-0.724
C4	0.004	0.511	0.325-0.804	<0.001	0.338	0.226-0.503
C_{68h}^{\dagger} ($< 0.2^*$ vs $\geq 0.2\mu\text{mol/L}$)	0.541	0.847	0.498-1.441	-	-	-
Leucovorin dose ($\leq 125^*$ vs $> 125\text{mg/m}^2$)	0.396	1.369	0.663-2.830	-	-	-
Actual infusion rate ($\leq 0.8^*$ vs > 0.8)	0.655	1.076	0.78-1.484	0.188	1.212	0.910-1.614
BSA ($\leq 0.69^*$ vs $> 0.69\text{m}^2$) [#]	0.024	0.697	0.510-0.953	0.855	1.039	0.69-1.563
C_{44h}^{\dagger} ($\mu\text{mol/L}$)				-	-	-
$< 0.5^*$	<0.001					
0.5-1.0	0.969	0.993	0.677-1.455	-	-	-
1.0-10	0.022	1.578	1.068-2.333	-	-	-
≥ 10	<0.001	6.437	3.145-13.174	-	-	-

*the reference group

[#]BSA, body surface area[†] C_{44h} : MTX concentration at 44h; C_{68h} : MTX concentration at 68h